RE:RE:RE:RE:RE:Sanofi ends collaboration with EvotecI agree the clinical trial results are material news and they must be made public if they were or made reference to at American Diabetes Association . So I would except on that front. As per comparing Bioveraativ purchase price of 11.6 billion dollars I just don’t see that kind of valuation for Sernova at this stage . Bioveraativ had revenues of 180 million per year and had a few drugs in their pipeline.
Serniova has to geat value for their indications diabetes, Hemophilia and Thyroid , Sernova has to show a clear path to commercializations and revenue streams before they get any kind of high valuation in my opinion. But I do think their immunosuppresion acquisition have made them a leader in their field of cell therapy/ device space . They need licensing agreements with cash involved , clear clinical trial results and pharma collaborations before they get ant decent valuation.
i do think that Semma acquisition by Vertex for $950 million US does set the floor at $1 Billion , any multiples would only be in case if a bidding war which is only speculation at this point.
just my thoughts.
Elgin